 |
|
|
| |
Safety and Efficacy of Ombitasvir, Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in Chronic Hepatitis C Patients Receiving Opioid Substitution Therapy: A Pooled Analysis Across 12 Clinical Trials
|
| |
| |
EASL: The PREVAIL Study: Intensive Models of HCV Care for People Who Inject Drugs - (04/26/17)....DOT, group treatment
EASL: Efficacy and safety of sofosbuvir/velpatasvir in people with chronic hepatitis C virus infection and recent injecting drug use: The SIMPLIFY study - (04/24/17)
C-EDGE CO-STAR: Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 12 Weeks in HCV-infected Persons Who Inject Drugs on Opioid Agonist Therapy.....http://www.natap.org/2016/EASL/EASL_107.htm
Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
Jason Grebely1, Massimo Puoti 2, Heiner Wedemeyer3, Curti s Cooper4, Mark S Sulkowski5, Graham Foster6, Thomas Berg7, Erica Villa8, Federico Rodriguez-Perez9, David L Wyles10, Negar N Alami11, Zhenzhen Zhang11, Emily Dumas11, Gregory J Dore1
1The Kirby Insti tute, UNSW Sydney, Sydney, Australia; 2Azienda Ospedaliera Ospedale Niguarda Ca' Granda, Milan, Italy; 3Medizinische Hochschule Hannover, Hannover, Germany; 4Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada; 5Viral Hepatitis Center, Johns Hopkins University, Baltimore, Maryland, United States; 6Queen Mary University of London and Barts Health NHS Trust, London, United Kingdom; 7Universitätsklinikum Leipzig, Leipzig, Germany;
8University of Modena and Reggio Emilia, Modena, Italy; 9Gastroenterology Department, VA Caribbean Healthcare System, San Juan, Puerto Rico; 10Infectious Diseases Division, Department of Medicine at Denver Health, Denver, Colorado, United States; 11AbbVie Inc., North Chicago, Illinois, United States
|
| |
|
|
|
|
|
